DiaKine Therapeutics
Norfolk
About DiaKine Therapeutics
DiaKine Therapeutics, Inc. is a development stage company commercializing novel immune modulators for the treatment of diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease. Therapeutics under development by DiaKine include: adjunct therapy to islet cell transplants (in Phase 2 clinical trial), halting the progression of type 1 diabetes in newly diagnosed adults, treatment and prevention of Latent Autoimmune Diabetes of Adults (LADA), treatment and prevention of insulin requiring type 2 diabetic, treatment and prevention of diabetes complications. DiaKine would like to thank the National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (NIDDK/NIH) for producing the clinical trials supplies for the trial.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Funding stage: M&A
- Last round: Seed (Sep 2008)
- Website: diakine.com
- Phone: (434)981-4777
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/diakine-therapeutics-1129093 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.